

# PHARMACEUTICALS AND MEDICAL DEVICES BUREAU OF INDIA (PMBI)

(Set up under the Department of Pharmaceuticals, Govt. of India)

8<sup>th</sup>& 9<sup>th</sup> Floor, Videocon Tower, Block E1, Jhandewalan Extension, New Delhi-110055

## Amendment no. 2

No.: -PMBI/DRUG/RC-208/2023/-II

DATE: 20/04/2023

**Tender No. PMBI/DRUG/RC-208/2023 dated 13/03/2023 for supply of Drugs to Pharmaceuticals & Medical Devices Bureau of India (PMBI) for two years under rate contract.**

**Reference: - i. Queries of Pre-Bid meeting held on 24/02/2023 at 15:30 Hours in the premises of PMBI.  
ii. Bidders query received through mails.**

Pharmaceuticals and Medical Devices Bureau of India (PMBI) has invited e-Bids from the interested parties for “e- Tender for Supply of Drugs for the year 2023- 2025”, vide Notice Inviting e-Tender No.- PMBI/DRUG/RC-208/2023. Detailed tender document containing eligibility criteria, selection mechanism, other terms and conditions are available on the website of Central Public Procurement Portal; [www.eprocure.gov.in](http://www.eprocure.gov.in) and PMBI Website; [www.janaushadhi.gov.in](http://www.janaushadhi.gov.in).

After considering the suggestions/ queries received from the prospective bidders, the clarifications/ amendments regarding the specification and packing in tender document have been made as per Part-A & Part-B. All other technical specifications, terms, and conditions along with the tender schedule as mentioned in tender document shall remain unchanged.

The following amendment in Tender Document is hereby authorized:

### Part-A

Sl. No.	Tender Clause/Reference	Query/Suggestion	Clarification/ Amendment
1	<b>Clause no. 3. A</b> Eligibility criteria (Technical bid -cover “A”) at page 8 of the tender document.	The prospective bidders requested to consider their earlier deposited EMD amount or rotate the same for this current tender as EMD amount.	<b><u>No Change</u></b> Tender condition prevails.
2	<b>Clause no. 3. Note (vi)</b> Eligibility criteria (Technical bid -cover “A”) at page 10 of the tender document.	The Existing clause no. 3. <b>Note (vi)</b> , is as follows:- “In case, if renewal application for Manufacturing License has been filled by the bidder or joint inspection has been carried out by the concerned Licensing Authority for the renewal of WHO-GMP certification and/or CoPP certification (as per official pharmacopoeia reference for such drug), scanned copy of same duly receipted by drug	Clause no. 3. Note (vi) is amended as: In case, if renewal application for Manufacturing License has been filed by the bidder or joint inspection has been carried out by the concerned Licensing Authority for the renewal of WHO-GMP certification and/or CoPP certification (any official pharmacopoeia), scanned copy of same duly receipted by drug authorities must be uploaded along with the validity certificate

		authorities must be uploaded along with the validity certificate from State Licensing Authority (SLA). It shall be issued before the last date of submission of tender by the Licensing Authority.”	from State Licensing Authority (SLA). <b><u>In case, if CoPP has been newly applied for the quoted product, the scanned copy of same duly receipted by drug authorities must be uploaded. However, Letter for award of Contract and purchase orders shall be issued only after submission of CoPP certificate for the awarded product or else the bid shall be considered invalid ab-initio. All above mentioned certificates should be issued before the last date of submission of tender by the Licensing Authority.</u></b>
3	<b>Clause no. 18 P.</b> Methodology For Placing Orders at page 19 of the tender document.	The prospective bidders requested to make the rate contract for one year instead of two years to avoid fluctuation in raw material prices.	<b><u>No Change</u></b> Tender condition prevails.
4	<b>Clause no. 24</b> Handling and Testing Charges at page 26 of the tender document.	The prospective bidders requested to reduce the existing testing charges from 1.5% to 1 % of the supply value.	<b><u>No Change</u></b> Tender condition prevails.

**Part - B: -**

**I: The following Amendment in Specification is hereby authorized: -**

Sl. No.	Tender Clause/ Reference	Sl. No. in the tender document	Drug Code	Generic Name of the Drug	Detailed Specification	Unit Size	Bidders Query	Amendment
1	Annexure - XII Clause 18 (M)	5	DC-482	Rabeprazole 20mg (Enteric Coated) and Levosulpiride 75mg (Sustained Release) Capsules	Each hard gelatin capsule contains: Rabeprazole Sodium IP 20 mg (as gastro-resistant pellets) Levosulpiride 75 mg (as Prolonged release pellets)	10's	The bidder requested to amend the specification as per generic name of the drug	Each hard gelatin capsule contains: Rabeprazole Sodium IP 20 mg (as Enteric coated pellets) Levosulpiride 75 mg (as Sustained release pellets)
	Annexure - XII Clause 18 (M)	48	DC-1522	Beclomethasone 0.025% w/w and Clotrimazole 1% w/w Cream	Beclomethasone 0.025% w/w Clotrimazole 1% w/w	20 gm Tube	The bidder requested to confirm the salt	Each Lami tube contains: Beclomethasone Dipropionate IP 0.025% w/w Clotrimazole IP 1% w/w Cream base q.s.
	Annexure - XII Clause 18 (M)	82	DC-1615	Erythromycin Stearate Tablets IP 500mg	Each Film-coated tablet contains: Erythromycin Stearate IP equivalent to Erythromycin 250 mg	10's	The bidder requested to amend the specification as per generic name of the drug	Each Film-coated tablet contains: Erythromycin Stearate IP equivalent to Erythromycin 500 mg
	Annexure - XII Clause 18	96	DC-1643	Insulin Glargine Injection IP 100 IU/ml (Mono	Each dispo-pen contains one 3 ml cartridge of Insulin Glargine Injection IP 100	3ml Prefilled Pen in mono	The bidder requested to amend the specification.	Each ml contains: Insulin glargine IP 100 IU

	(M)			component Insulin Glargine Recombinant DNA origin)	IU/ml: Each ml contains: Insulin glargine IP 100 IU Water for injection IP q.s	carton		
2	For all other queries regarding the specification of invited products i.e. DC- 1411, 1480, 1520, 1521, 1528, 1707, 1711, 1811, 1812, 1817, 1859, 2495 & 1841 there is no change in the specification and the tender condition prevails.							
3	For queries regarding the pack size of invited products i.e. DC- 1461, 1462, 1463, 1639, 1674, 1707, 1837 & 1841 there is no change in the pack size and the tender condition prevails.							

**All other contents of tender document remain unaltered. Bidders are requested to quote their rates considering all the terms and condition of the tender document including Amendment no. 1 dated 06/04/2023. Bidders are also requested to refer MoM of the pre-bid meeting for clarification.**

Sd/-  
DGM (Procurement& Quality)  
For & on behalf of PMBI  
Ph: 011-49431800(811)